-
公开(公告)号:US10556933B2
公开(公告)日:2020-02-11
申请号:US15238184
申请日:2016-08-16
Applicant: Affibody AB
Inventor: Lars Abrahmsén , Nina Herne , Christofer Lendel , Joachim Feldwisch
Abstract: Populations of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the scaffold amino acid sequence EXXXAXXEIX XLPNLTXXQX XAFIXKLXDD PSQSSELLSE AKKLNDSQ (SEQ ID NO: 1) or AKYAKEXXXAXX EIXXLPNLTX XQXXAFIXKL XDDPSQSSEL LSEAKKLNDS Q (SEQ ID NO: 2), wherein each X individually corresponds to an amino acid residue which is varied in the population are disclosed. Also populations of polynucleotides, wherein each member encodes a member of a polypeptide population are disclosed. Furthermore, combinations of such polypeptide populations and such polynucleotide populations are disclosed, wherein each member of polypeptide population is physically or spatially associated with the polynucleotide encoding that member via means for genotype-phenotype coupling.
-
公开(公告)号:US10323066B2
公开(公告)日:2019-06-18
申请号:US15510900
申请日:2015-09-17
Applicant: Affibody AB
Inventor: Lars Abrahmsén , Caroline Ekblad , Elin Gunneriusson , Torbjörn Gräslund , Johan Seijsing , John Löfblom , Malin Lindborg , Fredrik Frejd , Lindvi Gudmundsdotter
IPC: C07K14/31 , C07K14/00 , C07K14/735 , C07K14/74 , A61K38/00
Abstract: The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.
-
公开(公告)号:US10118949B2
公开(公告)日:2018-11-06
申请号:US14551931
申请日:2014-11-24
Applicant: Affibody AB
Inventor: Lars Abrahmsén , Andreas Jonsson , Jakob Dogan , Per-Åke Nygren
IPC: C07K14/00 , C07K14/61 , C07K14/535 , C07K14/755 , C07K16/18 , C07K14/31 , C07K14/315 , C07K14/605 , A61K38/00
Abstract: The present invention relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for the treatment of disease in mammals including humans.
-
公开(公告)号:US20160289337A1
公开(公告)日:2016-10-06
申请号:US14442603
申请日:2013-12-19
Applicant: AFFIBODY AB
Inventor: Lars Abrahmsén , Ingmarie Höidén-Guthenberg , Elin Gunneriusson
CPC classification number: C07K16/40 , C07K14/435 , C07K14/47 , C07K16/30 , C07K2317/92 , C07K2318/20
Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for carbonic anhydrase IX (CAIX), and provides a CAIX binding polypeptide comprising the sequence EX2X3X4AX6X7EIX10X11LPN LX16X17X18QX20 X21AFIX25X26LWD. The present disclosure also relates to the use of such a CAIX binding polypeptide as a diagnostic, prognostic agent and/or therapeutic agent.
Abstract translation: 本公开还涉及这种CAIX结合多肽作为诊断,预后剂和/或治疗剂的用途。
-
公开(公告)号:US20190284241A1
公开(公告)日:2019-09-19
申请号:US16377722
申请日:2019-04-08
Applicant: Affibody AB
Inventor: Lars Abrahmsén , Caroline Ekblad , Elin Gunneriusson , Torbjörn Gräslund , Johan Seijsing , John Löfblom , Malin Lindborg , Fredrik Frejd , Lindvi Gudmundsdotter
IPC: C07K14/00 , C07K14/735 , C07K14/74 , C07K14/31
Abstract: The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.
-
公开(公告)号:US20150158916A1
公开(公告)日:2015-06-11
申请号:US14551931
申请日:2014-11-24
Applicant: Affibody AB
Inventor: Lars Abrahmsén , Andreas Jonsson , Jakob Dogan , Per-Åke Nygren
IPC: C07K14/00 , C07K16/18 , C07K14/535 , C07K14/755 , C07K14/605 , C07K14/61
CPC classification number: C07K14/00 , A61K38/00 , C07K14/31 , C07K14/315 , C07K14/535 , C07K14/605 , C07K14/61 , C07K14/755 , C07K16/18 , C07K2319/00 , C07K2319/70
Abstract: The present invention relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for the treatment of disease in mammals including humans.
Abstract translation: 本发明涉及一类对白蛋白具有结合亲和性的工程化多肽。 它还涉及利用这些和其它化合物在不同背景下结合白蛋白的新方法和用途,其中一些对于包括人在内的哺乳动物的疾病的治疗具有重要意义。
-
公开(公告)号:US08883120B2
公开(公告)日:2014-11-11
申请号:US13928522
申请日:2013-06-27
Applicant: Affibody AB
Inventor: Lars Abrahmsén , Nina Herne , Joachim Feldwisch , Christofer Lendel , Vladimir Tolmachev
CPC classification number: A61K51/08 , A61K38/00 , A61K51/088 , C07K16/32
Abstract: HER2 binding polypeptides comprising the amino acid sequence EX1 RNAYWEIA LLPNLTNQQK RAFIRKLYDD PSQSSELLX2E AKKLNDSQ wherein X1 in position 2 is M, I or L, and X2 in position 39 is S or C (SEQ ID NO:1) are disclosed. Moreover, such peptides comprising a chelating environment are disclosed. Also radiolabeled polypeptides formed by the peptides comprising a chelating environment and radionuclides are disclosed. Furthermore, methods of in vivo imaging of the body of a mammalian subject having or suspected of having a cancer characterized by overexpression of HER2 comprising administration of such a radiolabeled polypeptide followed by obtainment of an image of the body using a medical imaging instrument and also methods of treating such cancer are disclosed. Furthermore, the use of such a radiolabeled polypeptide in diagnosis and treatment of cancer characterized by overexpression of HER2. Nucleic acids encoding the polypeptides, expression vectors comprising the nucleic acids and host cells comprising the expression vectors are also disclosed.
Abstract translation: HER2结合多肽包含氨基酸序列EX1 RNAYWEIA LLPNLTNQQK RAFIRKLYDD PSQSSELLX2E AKKLNDSQ,其中位置2中的X1是M,I或L,而位置39的X2是S或C(SEQ ID NO:1)。 此外,公开了包含螯合环境的这些肽。 还公开了由包含螯合环境和放射性核素的肽形成的放射性标记的多肽。 此外,具有或怀疑具有HER2过表达的哺乳动物受试者的身体的体内成像方法包括施用这种放射性标记的多肽,然后使用医学成像仪获得身体的图像,以及方法 公开了治疗这种癌症的方法。 此外,这种放射性标记的多肽在诊断和治疗HER2过表达的癌症中的应用。 还公开了编码多肽的核酸,包含核酸的表达载体和包含表达载体的宿主细胞。
-
公开(公告)号:US20180230235A1
公开(公告)日:2018-08-16
申请号:US15938424
申请日:2018-03-28
Applicant: AFFIBODY AB
Inventor: Lars Abrahmsén , Ingmarie Höidén-Guthenberg , Elin Gunneriusson
IPC: C07K16/40 , C07K14/47 , C07K14/435 , C07K16/30
CPC classification number: C07K16/40 , C07K14/435 , C07K14/47 , C07K16/30 , C07K2317/92 , C07K2318/20
Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for carbonic anhydrase IX (CAIX), and provides a CAIX binding polypeptide comprising the sequence EX2X3X4AX6X7EIX10X11LPN LX16X17X18QX20X21AFIX25X26LWD (SEQ ID NO. 369). The present disclosure also relates to the use of such a CAIX binding polypeptide as a diagnostic, prognostic agent and/or therapeutic agent.
-
公开(公告)号:US20130280164A1
公开(公告)日:2013-10-24
申请号:US13928522
申请日:2013-06-27
Applicant: AFFIBODY AB
Inventor: Lars Abrahmsén , Nina Herne , Joachim Feldwisch , Christofer Lendel , Vladimir Tolmachev
IPC: A61K51/08
CPC classification number: A61K51/08 , A61K38/00 , A61K51/088 , C07K16/32
Abstract: HER2 binding polypeptides comprising the amino acid sequence EX1 RNAYWEIA LLPNLTNQQK RAFIRKLYDD PSQSSELLX2E AKKLNDSQ wherein X1 in position 2 is M, I or L, and X2 in position 39 is S or C (SEQ ID NO:1) are disclosed. Moreover, such peptides comprising a chelating environment are disclosed. Also radiolabeled polypeptides formed by the peptides comprising a chelating environment and radionuclides are disclosed. Furthermore, methods of in vivo imaging of the body of a mammalian subject having or suspected of having a cancer characterized by overexpression of HER2 comprising administration of such a radiolabeled polypeptide followed by obtainment of an image of the body using a medical imaging instrument and also methods of treating such cancer are disclosed. Furthermore, the use of such a radiolabeled polypeptide in diagnosis and treatment of cancer characterized by overexpression of HER2. Nucleic acids encoding the polypeptides, expression vectors comprising the nucleic acids and host cells comprising the expression vectors are also disclosed.
Abstract translation: HER2结合多肽包含氨基酸序列EX1 RNAYWEIA LLPNLTNQQK RAFIRKLYDD PSQSSELLX2E AKKLNDSQ,其中位置2中的X1是M,I或L,而位置39的X2是S或C(SEQ ID NO:1)。 此外,公开了包含螯合环境的这些肽。 还公开了由包含螯合环境和放射性核素的肽形成的放射性标记的多肽。 此外,具有或怀疑具有HER2过表达的哺乳动物受试者的身体的体内成像方法包括施用这种放射性标记的多肽,然后使用医学成像仪获得身体的图像,以及方法 公开了治疗这种癌症的方法。 此外,这种放射性标记的多肽在诊断和治疗HER2过表达的癌症中的应用。 还公开了编码多肽的核酸,包含核酸的表达载体和包含表达载体的宿主细胞。
-
公开(公告)号:US09957330B2
公开(公告)日:2018-05-01
申请号:US14442603
申请日:2013-12-19
Applicant: AFFIBODY AB
Inventor: Lars Abrahmsén , Ingmarie Höidén-Guthenberg , Elin Gunneriusson
IPC: C07K16/40 , C07K16/30 , C07K14/47 , C07K14/435
CPC classification number: C07K16/40 , C07K14/435 , C07K14/47 , C07K16/30 , C07K2317/92 , C07K2318/20
Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for carbonic anhydrase IX (CAIX), and provides a CAIX binding polypeptide comprising the sequence EX2X3X4AX6X7EIX10X11LPN LX16X17X18QX20 X21AFIX25X26LWD. The present disclosure also relates to the use of such a CAIX binding polypeptide as a diagnostic, prognostic agent and/or therapeutic agent.
-
-
-
-
-
-
-
-
-